Raymond James Financial
HUMA icon

Raymond James Financial’s Humacyte HUMA Stock Holding History

Raymond James Financial’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9K Buy
49,802
+1,473
+3% +$1.36K ﹤0.01% 5284
2026
Q1 		$29.3K Sell
48,329
-3,000
-6% -$3.12K ﹤0.01% 5176
2025
Q4 		$49.3K Sell
51,329
-20,799
-29% -$29.5K ﹤0.01% 5012
2025
Q3 		$126K Buy
72,128
+61,017
+549% +$120K ﹤0.01% 4713
2025
Q2 		$23.2K Sell
11,111
-6,856
-38% -$13.2K ﹤0.01% 5537
2025
Q1 		$30.6K Sell
17,967
-56,731
-76% -$213K ﹤0.01% 4683
2024
Q4 		$377K Buy
+74,698
New +$370K ﹤0.01% 4058

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James Financial's HUMA Position: Q2 2026 in Review

Raymond James Financial increased its Humacyte (HUMA) stake by 3% in Q2 2026, buying an estimated $1.36K and bringing the position to 49,802 shares worth $38.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5284.

Raymond James Financial first reported a position in HUMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $377K in Q4 2024. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Raymond James Financial held 49,802 shares of Humacyte worth $38.9K as of Q2 2026.
  • Raymond James Financial bought 1,473 Humacyte shares in Q2 2026, an estimated $1.36K.
  • Humacyte made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5284 holding.
  • Raymond James Financial first reported a position in Humacyte in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Humacyte position peaked at $377K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.